Targeted Delivery of Iomab-B to the Marrow in Patients with R/R AML
Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.
Rajneesh Nath, MD, a medical oncologist with Banner Health, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia (AML) population. His findings were presented at the 2021 Transplantation & Cellular Therapy Meetings.
According to Nath, the 2 most common types of stem cell transplantation are myeloablation and reduced intensity. Myeloablation is associated with increased intensity of chemotherapy and higher doses of radiation. This tends to increase the toxicity of treatment for the patient.
Nath’s hypothesis that delivery of Iomab-B directly to where it is needed can help reduce toxicity and save critical organs such as the heart, lungs and kidney. The study found that Iomab-B was able to spare the gastrointestinal tract. According to Nath, instances of sepsis in the Iomab-B group was 4% while in the standard of care group, it was 13%.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
